Previous 10 | Next 10 |
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization Comparable survival benefits were also shown compared to ENCALS predicted median survival C ...
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegener...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
A Salt Lake City-based %Biotech company found tremendous success on Wednesday after %Oppenheimer adjusted its price target to $17.00 from $16.00. While this $1 move isn’t necessarily groundbreaking news, the fact that shares are currently trading around $4.00, traders couldn&...
Turquoise Hill Resources ( TRQ ) -18% after Turquoise Hill rejects Rio Tinto's bid to take control of huge Mongolia mine . Arcadia Biosciences ( RKDA ) -18% to raise $5M in securities offering . Root ( ROOT ) -17% . TREASURE GLOBAL ( TGL ...
Clinical-stage biotech Clene Inc. ( NASDAQ: CLNN ) dropped ~14% in the pre-market Monday after the company announced data for its lead candidate CNM-Au8 from a Phase 2 trial involving patients with relapsing-remitting multiple sclerosis (RRMS). The VISIONARY-MS trial cam...
Clene press release ( NASDAQ: CLNN ): Q2 GAAP EPS of -$0.07. Revenue of $0.03M. Clene’s cash, cash equivalents and marketable investments securities totaled $26.3M as of Jun. 30, 2022, compared to $50.3M as of Dec. 31, 2021. For further details see: Cl...
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT population Consistent improvements favoring CNM-Au8 were seen across para...
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM- Au8 ® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerativ...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...